Meeting
2014 ASCO Annual Meeting
Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies: HOG LUN 07-130.
Authors
Shadia Ibrahim Jalal
Indiana University School of Medicine, Indianapolis, IN
Shadia Ibrahim Jalal , Nasser H. Hanna , Robin Zon , Gregory A. Masters , Hossein Borghaei , Karuna Koneru , Sunil S. Badve , Nagendra K Prasad , Neeta Somaiah , Jingwei Wu , Zhangsheng Yu , Lawrence H. Einhorn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00890955
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7594)
DOI
10.1200/jco.2014.32.15_suppl.7594
Abstract #
7594
Poster Bd #
202
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
A phase I study of amrubicin (AMR) and cyclophosphamide in patients with advanced solid organ malignancies: A trial from the Hoosier Oncology Group.
First Author: S. I. Jalal
Poster
2024 ASCO Annual Meeting
Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.
First Author: Justin M. Watts
Poster
2023 ASCO Annual Meeting
Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.
First Author: Justin M. Watts
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk